benevolent.com
Get leads like Benevolent — and thousands more
Build targeted lists by tech stack, traffic, and more
BenevolentAI: The $292M AI Bet on Drug Discovery
How a 494-person team is rewriting biopharma's playbook with artificial intelligence
In a world where drug discovery takes 10+ years and costs billions, BenevolentAI isn't just another biotech—it's a data-driven weapon aimed at the industry's inefficiencies. With $292M in funding and a public listing on Euronext Amsterdam, they're betting that AI can compress R&D timelines from decades to months.
"They're not just building AI tools—they're building a biopharma company powered by AI, from target identification to clinical development."
The Traffic Paradox
With only 16,197 monthly visits, BenevolentAI's traffic seems modest for a $292M-funded company. But this reveals their true focus: they're not a consumer-facing platform. Their audience is pharmaceutical executives, R&D partners, and investors—people searching specifically for 'benevolentai' (1,640 monthly searches). The 35% direct traffic suggests strong brand recognition among industry insiders who know exactly where to find them.
The Strategic Pivot
BenevolentAI's journey from general AI platform to focused biopharma player tells a critical story. Originally positioned as a broad AI company, they've narrowed to drug discovery with clinical-stage assets. Their tech stack (Vite, Tailwind, jQuery) shows a modern web presence, but the real innovation is in their platform that maps knowledge graphs across 25+ biomedical data sources. This isn't a SaaS product—it's a drug discovery engine.
The leadership team reveals their hybrid strategy: Michael Brennan (CSO/CFO) bridges finance and science, while Ivan Griffin (Co-founder/CBO) drives business development. Their VP-level expertise spans clinical development (Judit Molnar) and discovery safety (Amanda Giddings)—indicating they're not just an AI layer, but a full-stack biopharma operation with internal pipeline candidates.
- Publicly traded (BAI) on Euronext Amsterdam—rare for pure-play AI biotech
- Hybrid model: both internal drug pipeline and platform licensing
- Strong leadership bench with both AI and traditional biopharma expertise
- Focused on high-value therapeutic areas with unmet medical needs
The Verdict: High-Risk, High-Reward AI Bet
BenevolentAI proves that AI drug discovery requires more than algorithms—it needs deep biopharma expertise and patient capital. For investors, it's a direct bet on AI accelerating the 10-year drug timeline. For founders, it's a case study in strategic focus: from broad AI to targeted therapeutics. The real test? Whether their platform can consistently produce clinical candidates faster than traditional methods. With $107M in revenue and a pipeline advancing through trials, they're one of the few AI biotechs walking the talk.
What tech stack does Benevolent use?
How much traffic does Benevolent get?
Traffic & Engagement
Traffic Sources
Where is Benevolent's audience located?
What keywords does Benevolent rank for?
5 keywordsHow is Benevolent's SEO?
Open Graph Image
https://www.benevolent.com/application/files/1316/7603/3712/HomePage_1.jpg
Meta Tags
BenevolentAI | AI Drug Discovery | AI Pharma
BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery.
BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery.
H1 Tags
What is Benevolent's revenue?
Who competes with Benevolent?
Who works at Benevolent?
Loading leads...
What do customers think of Benevolent?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Benevolent
What is Benevolent's Revenue?
What does Benevolent do?
How fast is Benevolent growing?
What technologies does Benevolent use?
Who are Benevolent's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
How to contact Benevolent?
Contact Information
Export benevolent.com Data
Download the complete tech stack, analytics, leads, and company data for benevolent.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About benevolent.com
BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery.
Company Overview
benevolent.com Social Media
Contact benevolent.com
Phone Numbers
Technology Stack
benevolent.com uses 10 technologies across their website including Font Awesome, Google Fonts, PHP, Cookiebot, and more.
Fonts
Font Awesome, Google Fonts
Programming Languages
PHP
Privacy & Consent
Cookiebot
Analytics & Marketing
Google Tag Manager
Build Tools
Vite
UI Libraries
DaisyUI
Traffic & Audience
benevolent.com receives approximately 16.2K monthly visitors and ranks #1,673,915 globally. The website has a bounce rate of 47% with visitors viewing an average of 1.5 pages per visit. Users spend an average of 0:10 on the site.
The majority of benevolent.com's traffic comes from undefined, undefined, .
Frequently Asked Questions
What is benevolent.com?
What technologies does benevolent.com use?
How do I contact benevolent.com?
What are benevolent.com's social media accounts?
How popular is benevolent.com?
Related Searches
This page provides publicly available information about benevolent.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit benevolent.com directly at https://benevolent.com.